Novo Nordisk A/S (NYSE:NVO)
| 107.66 Delayed Data As of May 20 |  -0.09 / -0.08%Today’s Change | 78.71 Today|||52-Week Range 122.16 | -3.88% Year-to-Date |
Latest NVO News | Press Releases
| Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo May 20 / Zacks.com - Paid Partner Content | Teva Pharmaceutical Industries: Why Investors Should Buy the Dip May 16 / StockNews.com - Paid Partner Content |
| Is Perrigo a Buy After Reporting Q1 Earnings? May 20 / StockNews.com - Paid Partner Content | Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod May 16 / Zacks.com - Paid Partner Content |
| 4 Large Drug Stocks to Watch as the Industry Recovers May 19 / Zacks.com - Paid Partner Content | How Novo Nordisk Will Protect Insulin Sales May 12 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 107.75 |
| Today’s open | 106.48 |
| Day’s range | 106.36 - 108.16 |
| Volume | 1,731 |
| Average volume (3 months) | 1,509,691 |
| Market cap | $187.3B |
Data as of 4:49pm ET, 05/20/2022
Growth & Valuation
| Earnings growth (last year) | +19.70% |
| Earnings growth (this year) | +7.43% |
| Earnings growth (next 5 years) | +14.39% |
| Revenue growth (last year) | +15.27% |
| P/E ratio | 35.3 |
| Price/Sales | 11.53 |
| Price/Book | 22.69 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NVSNovartis | +0.01 | +0.01% |
| AZNAstraZeneca | +1.67 | +2.59% |
| BMYBristol-Myers Squibb | +0.01 | +0.01% |
| MRKMerck | -0.04 | -0.04% |
Data as of 4:49pm ET, 05/20/2022
Financials
| Next reporting date | August 4, 2022 |
| EPS forecast (this quarter) | $0.83 |
| Annual revenue (last year) | $22.4B |
| Annual profit (last year) | $7.6B |
| Net profit margin | 33.92% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bagsværd, Capital Region |
Forecasts
